Securisyn Medical

Patented interlocking medical devices prevent costly & deadly tube dislodgement

Claim My Business
Security Type
Crowd SAFE
Min Investment
Offering Date
October 31, 2022
Expected Close Date
December 31, 2022
Target Raise
No. Investors
Security Price
Number of Employees
Short Term Debt
Cost of Goods
Long Term Debt
Net Income

Company Description

In health care, a significant threat to ventilated patient safety is unplanned extubation, which occurs when a patient or other external force pulls an inadequately stabilized breathing tube out of the airway.


1 investor
Annual Video Teleconference Call with Senior Management
Limited (499 left of 500)

Securisyn Challenge Coin
Limited (100 left of 100)

Key Deal Facts

Securement devices for breathing tubes & other medical tubes & catheters
Exclusive global manufacturing & distribution partnership with SunMed
Premier Breakthrough Technology Contract validates award-winning technology
Addresses $5B+ problem leading to 160K+ injuries & 30K+ deaths in US/year
$4M non-dilutive funding from Air Force, NIH to advance & expand portfolio
Co-development partnerships w/ best-in-class hospitals: Mayo Clinic, CHLA
Deep IP portfolio w/ 13 issued & pending patents guarding key technologies


1 investor
Annual Video Teleconference Call with Senior Management
Limited (499 left of 500)

Securisyn Challenge Coin
Limited (100 left of 100)

Management Team / Advisory Board Bios

Mark Bruning
President & CEO, Manager
CEO, AMR & Professional Pediatric Homecare / MBA from Northwestern

Arthur Kanowitz, MD FACEP
Co-Founder, Chairman, Chief Medical Officer
46-Year Career in Emergency Medicine
Past State of Colorado EMS & Trauma Medical Director

Elyse Blazevich
Co-Founder, Manager
President & CEO Colorado BioScience Association / MSOL from Colorado State University

Bruno Darre
Independent Manager
Chairman & CEO 73 Holdings / Co-Founder Bow River Capital Partners

Troy Noem
Independent Manager
Chief Financial Officer Nuclear Care Partners

Patrick Howe
Chief Commercialization Officer
Med device industry executive with a combined 34 years of clinical and product commercialization experience

Nam Trinh
Chief Operating Officer
Med device leader with expertise in quality, regulatory compliance, engineering & supply chain

Alan Greene, RRT
Chief Marketing Officer
Respiratory Care Professional with 30+ years of Med Tech clinical, sales, marketing and BD

Scott Bourn, PhD
VP of Clinical Quality & Impact
Clinical, educational & operational evidence to improve outcomes & reduce cost / MS in Critical Care Nursing, PhD

Greg Letendre
VP of Business Development Federal Sector
 PM and BD professional with 25+ years experience in military, federal & commercial markets

Katie McIntyre
Senior Manager, Product Development
Experienced medical device project engineer
BS Mechanical Engineering from Univ. of Notre Dame

Stephanie Escobedo
Senior Manager, Finance & Administration
Experienced accountant skilled in improving compliance and streamlining operations

Contract Clinical Specialist

Megan Palato, RN
Contract Clinical Specialist

Doug Kupas, MD
Medical Advisor

Ashley Lachowicz, RRT
Medical Advisor

Michael Gentile, RRT
Medical Advisor
Amount Raised : $112,381
Reveal the Score by Voting
Not enough ratings to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.

Security Description

An equity crowdfunding specific version of a SAFE used by crowdfunding portal Republic. Upon conversion (if and when that happens), investors may receive special shares with limited rights that do not show up on a company’s cap table. The issuer may roll over and not convert shares at the next financing round causing investors to lose out on some upside.

Research Reports

No reports have been submitted

Become a Reporter